This page shows the latest Novo-Nordisk news and features for those working in and with pharma, biotech and healthcare.
The two companies first announced their NASH collaboration in 2019. Gilead and Novo Nordisk have planned a new phase 2b trial in a bid to expand their clinical collaboration in ... Gilead is pleased to expand our collaboration with Novo Nordisk and
Among these is tirzepatide, which recently yielded positive results in a head-to-head trial against Novo Nordisk’s semaglutide in type 2 diabetes.
Eli Lilly’s investigational treatment tirzepatide beat Novo Nordisk’s semaglutide in a head-to-head trial in type 2 diabetes across a number of measures, the company announced. ... Novo has already filed once-weekly semaglutide for weight management
Since its launch, the agency now operates in 18 countries, with a number of leading global pharma companies now using its services, including the likes of Bayer, Novo Nordisk and Boehringer
Novo Nordisk added that semaglutide has been shown to reduce measures of neuro-inflammation, which may affect cognition and function in Alzheimer’s patients. ... said Mads Krogsgaard Thomsen, executive vice president and chief scientific officer at
Sponsored by: Makara Health. Winner: Diabetes Knowledge in Practice by Liberum IME with support from multiple supporters, including Novo Nordisk A/S and MSD.
More from news
Approximately 149 fully matching, plus 288 partially matching documents found.
Self-administered injectables, such as Novo Nordisk’s recently approved therapy for adult growth hormone deficiency (GHD), Sogroya (somapacitan), and Novartis’ much-hyped MS treatment, Kesimpta (ofatumumab), will be tested in
Around the same time (late 2018), Novo Nordisk launched Ozempic, also for type 2 diabetes, though a different class (GLP1).
Meanwhile, Novo Nordisk has launched Rybelsus (semaglutide) oral tablets to improve control of blood sugar – but specifically alongside diet and exercise.
UCB has reconfigured its teams around Patient Value Units. Novo Nordisk has established Disease Experience Expert Panels (DEEP), an approach based on ‘an evolving world view where people with serious chronic
Novo Nordisk’s Biopharm is showing solid growth after a stuttering start, and its new leader believes a ‘sleeping beauty’ has been awoken. ... The small revolution we are also running in Novo Nordisk is to realise that we have many platforms at our
More from intelligence
Approximately 6 fully matching, plus 41 partially matching documents found.
He has previously worked in various positions at Novo Nordisk, most recently as its Senior Global Regulatory Lead. ... During his time at Novo Nordisk, he led the strategic regulatory input for the orphan drug NovoEight from phase 1 through phase 3.
The latest med comms movers. Ashfield appoints Novo’s sales and marketing director. ... Van Weperen was most recently at diabetes giant Novo Nordisk, where he worked on delivering insulin and GLP1 biosimilar defence strategies, leading Novo’s UK
Thomas has previously held senior positions at Novo Nordisk including head of sales North, UK.
He will take up the new role 1 July. Former Novo Nordisk CEO Lars Rebien Sørensen has been appointed as Novo Holdings’ new chairman. ... years. Sørensen will succeed Sten Scheibye - who retires effective 1 July - and he will also become chairman of
He said: “I am delighted to join Novo Nordisk in the role of general manager in the UK. ... The vision, values and passion that is immediately evident within the company makes Novo Nordisk and exciting organisation to be a part of.
More from appointments
Approximately 10 fully matching, plus 36 partially matching documents found.
Why not just be human and accept our shortcomings? An ex-client of mine, Liz Skrbkova, from the US Obesity Portfolio Communications team at Novo Nordisk, and HBA Rising Star (2020),
She also holds a level 5 CIPD in HR management achieved during her time at Novo Nordisk. .
Combining proprietary data, a proven behaviour change methodology and emotive, award-winning creative, the new agency gives clients including Bayer, Holland &Barrett, Novo Nordisk and Sanofi access to a broad range
In the latest episode of Impetus Digital's Fireside Chat, I sit down with Frank Armenante, Director of Commercial Execution at Novo Nordisk.
Johnson and Johnson. University of Leeds. Lundbeck Mind. MSD. Novo. Nordisk.
More from PMHub
Approximately 3 fully matching, plus 48 partially matching documents found.
No results were found
A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...